|
G. Lambert was awarded a PhD in Pathophysiology from the University of Paris in 1998. He specialized in lipidology, as a post-doctoral fellow at the Molecular Disease Branch of the NIH (Bethesda MD, USA) and as a senior research fellow at the Heart Research Institute (Sydney, Australia).
Since 2002, G. Lambert has conducted seminal research projects on PCSK9, a protein that targets the LDL receptor for intracellular degradation, and the target of novel cholesterol lowering therapies. He has investigated the cellular pathways by which PCSK9 modulates the circulating levels of lipoprotein (a). Gilles Lambert is currently Professor in Cell Biology and Biochemistry at the University of La Réunion Medical School (France) and a principal investigator at Inserm UMR1188 DéTROI laboratory Scientific summaryPr. Lambert current research interests are to decipher the molecular pathways modulating lipoprotein (a), to understand the role of PCSK9 in the peripheral nervous system, and to investigate personalized medicine approaches for familial hypercholesterolemia.
|
PUBLICATIONS
1. M Roudaut, A Caillaud, L Bray, A Girardeau, A Rimbert, M Croyal, G Lambert, G Delpouve, E Vandenhaute, Z Souguir, C LeMay, N Maubon, B Cariou, K Si-Tayeb (2024) “hiPSC-derived liver organoids grown on a Biomimesys® Hyaluronic Acid-based hydro-scaffold as a new model for studying human lipoprotein metabolism levels” Bioengineering & Translational Medicine 9, e10659
2. G Lambert, SG Pfisterer (2025) “The molecular structure of LDL has finally been elucidated” Nat Rev Cardiol 22, 313-314.
3. G Lambert, MB Boffa (2025) “Why has the Lp(a) receptor proven so elusive?” Atherosclerosis. 404, 119189.
4. K Chemello, AF Guedon, R Techer, AK Jaafar, S Guilhen, MJ Swietek, G Lambert, A Gallo (2025) “Apolipoprotein E plasma concentrations are predictive of recurrent strokes - Insights from the SPARCL trial” J Am Heart Assoc 13, e036630.
5. AK Jaafar, A Paulo-Ramos, G Rastoldo, B Veeren, C Planesse, M Bringart, P Rondeau, K Chemello, O Meilhac, G Lambert, S Bourane (2025) “PCSK9 deficiency promotes the development of peripheral neuropathy” JCI Insight 10, e183786.
6. AK Jaafar, S Bourane, G Lambert, K Chemello (2026) “Lipoprotein (a) in Familial Hypercholesterolemia” Curr. Opin. Lipidol. 37, 93-99.
7. A Al Khaifi, Kh Al-Waili, B Al-Shaiban, H Al-Sabti, A Al-Riyami, M Al-Kindi, F Zadjali, K Al-Saidi, F Al-Kindi, H Al-Lawati, K Al-Hashmi, A Al-Zadjali, R Al-Zadjali, S Al-Hasari, R Techer, K Chemello, M Mukaddirov, K Al-Farsi, H Al-Riyami, S Al-Mukhaini, H Al-Badi, M Al-Saleh, ER Abdelmonaem, I Al-Zakwani, GC Lambert, K Al-Rasadi (2026) “Elevated Lipoprotein (a) and Large Apo(a) Isoforms in Omani Patients: a Distinct Cardiovascular Risk Profile” Am J Prev Cardiol doi: 10.1016/j.ajpc.2026.101781
2. G Lambert, SG Pfisterer (2025) “The molecular structure of LDL has finally been elucidated” Nat Rev Cardiol 22, 313-314.
3. G Lambert, MB Boffa (2025) “Why has the Lp(a) receptor proven so elusive?” Atherosclerosis. 404, 119189.
4. K Chemello, AF Guedon, R Techer, AK Jaafar, S Guilhen, MJ Swietek, G Lambert, A Gallo (2025) “Apolipoprotein E plasma concentrations are predictive of recurrent strokes - Insights from the SPARCL trial” J Am Heart Assoc 13, e036630.
5. AK Jaafar, A Paulo-Ramos, G Rastoldo, B Veeren, C Planesse, M Bringart, P Rondeau, K Chemello, O Meilhac, G Lambert, S Bourane (2025) “PCSK9 deficiency promotes the development of peripheral neuropathy” JCI Insight 10, e183786.
6. AK Jaafar, S Bourane, G Lambert, K Chemello (2026) “Lipoprotein (a) in Familial Hypercholesterolemia” Curr. Opin. Lipidol. 37, 93-99.
7. A Al Khaifi, Kh Al-Waili, B Al-Shaiban, H Al-Sabti, A Al-Riyami, M Al-Kindi, F Zadjali, K Al-Saidi, F Al-Kindi, H Al-Lawati, K Al-Hashmi, A Al-Zadjali, R Al-Zadjali, S Al-Hasari, R Techer, K Chemello, M Mukaddirov, K Al-Farsi, H Al-Riyami, S Al-Mukhaini, H Al-Badi, M Al-Saleh, ER Abdelmonaem, I Al-Zakwani, GC Lambert, K Al-Rasadi (2026) “Elevated Lipoprotein (a) and Large Apo(a) Isoforms in Omani Patients: a Distinct Cardiovascular Risk Profile” Am J Prev Cardiol doi: 10.1016/j.ajpc.2026.101781